Delving into the Latest Updates on Venus Remedies Ltd. with Synapse

Overview

Tags

Infectious Diseases

Other Diseases

Urogenital Diseases

Small molecule drug

Chemical drugs

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	8
Nervous System Diseases	2
Hemic and Lymphatic Diseases	2
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	14
Chemical drugs	4
Herbal medicine	3
Unknown	1

Top 5 Target	Count

PBPs x β-lactamase	2
30S subunit x PBPs	1
β-lactamase(Beta Lactamase)	1
ETB(Endothelin receptor type B)	1
NF-κB(Nuclear factor NF-kappa-B complex)	1

A Double-blind, Randomized, Two-period, Two-treatment, Two-sequence, Crossover, Balanced, Single Subcutaneous Dose Pharmacodynamic Comparative Equivalence Study of Enoxaparin Sodium Pre-filled Syringes BP (Injection) 40 mg/0.4 ml (4,000 IU/0.4 mL) of Venus Remedies Limited, India and 'Clexane®' (Enoxaparin Sodium Injection Solution in a Pre-filled Syringe) 4,000 IU (40 mg)/0.4 ml of Sanofi, Germany in Healthy Adult Human Subjects Under Fasting Conditions

This is a single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced, pharmacodynamic (PD) study with 7 days wash-out period. The objective of this study is to assess the bioequivalence between the Enoxaparin (Venus Remedies Limited, India) and its innovator product (Clexane®, Sanofi, Germany).

Start Date26 Feb 2021

Sponsor / Collaborator

Venus Remedies Ltd.

NCT03477422 / CompletedPhase 3

Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria

The purpose of this study is to evaluate the effects of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) compared to Meropenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis caused by β-lactamase producing gram-negative bacteria

Start Date11 Jan 2014

Sponsor / Collaborator

Venus Remedies Ltd.

CTRI/2012/08/002899 / CompletedNot Applicable

An Open-Labelled PK-PD Study of ELORES in infections caused by ESBL producing gram-negative bacteria

Start Date20 Aug 2013

Sponsor / Collaborator

Venus Remedies Ltd.

100 Clinical Results associated with Venus Remedies Ltd.

Login to view more data

0 Patents (Medical) associated with Venus Remedies Ltd.

Login to view more data

12

Literatures (Medical) associated with Venus Remedies Ltd.

15 Sep 2010·Asian Journal of Biochemistry

Effect of Sub-Acute Intravenous Injection of Endothelin Receptor Agonist IRL-1620 in Mice

Author: Arora, P. ; Chaudhary, M. ; Sehgal, R. ; Kharb, N.

The present study was conducted to evaluate effect of sub-acute i.v. injection of ET_B receptor agonist IRL-1620 in mice.Swiss albino mice (n = 24, weighing 20-25 g) were divided into two groups (12 animal each), control group (0 μg kg^-1) and IRL-1620 treated group (1 μg/kg/min, i.v., for 30 days).Each group was further subdivided into two groups depending on sex of mice having 6 animals each.No significant change in animal body weight, hemogram, liver function test and renal function tests was observed on treatment with IRL-1620.Histol. examination of liver was normal and Kidneys showed mild congestion.In conclusion, sub-acute dose (1 μg/kg/min, i.v.) of endothelin receptor agonist ET_B IRL-1620 did not cause toxic effect on liver and kidney.

15 Dec 2009·International Journal of Biomedical Science

A 28-Days Sub-Acute Toxicity Study in Swiss Albino Mice to Evaluate Toxicity Profile of Neurotol Plus (Mannitol and Glycerol Combination)

Author: Anupama Tamta ; Rajesh Sehgal ; Manu Chaudhary

Osmotic agents are still the most common treatment options available for controlling intracranial pressure (ICP). Combining Mannitol and Glycerol provides a better alternative and is currently available as best therapy used for increased ICP. The aim of this work was to study the effects of repeated dosing (28 days) of Mannitol 20% and Glycerol 10% combined formulation, Neurotol plus on safety profile. A twenty eight days sub-acute toxicity study was conducted at three different dose levels of 5ml/kg, 10 ml/kg and 20 ml/kg. Mice were randomly divided into four groups of six animals each. Physical parameters, biochemical parameters related to liver toxicity & nephrotoxicity and hematological parameters were studied as end point of evaluation. We also carried out histopathlogical studies to assess any organ specific toxicity. The present study demonstrated that there were either no or very minimal changes (at high dose) were observed on various physical, biochemical and hematological parameters between Neurotol plus and control group. In conclusion the data of present study suggest that the combination of Mannitol and Glycerol is not associated with any serious adverse effects and is safe therapeutic choice for ICP reduction.

01 Dec 2009·International journal of biomedical science : IJBS

A 28-days sub-acute toxicity study in swiss albino mice to evaluate toxicity profile of neurotol plus (mannitol and glycerol combination).

Article

Author: Sehgal, Rajesh ; Tamta, Anupama ; Chaudhary, Manu

Osmotic agents are still the most common treatment options available for controlling intracranial pressure (ICP). Combining Mannitol and Glycerol provides a better alternative and is currently available as best therapy used for increased ICP. The aim of this work was to study the effects of repeated dosing (28 days) of Mannitol 20% and Glycerol 10% combined formulation, Neurotol plus on safety profile. A twenty eight days sub-acute toxicity study was conducted at three different dose levels of 5ml/kg, 10 ml/kg and 20 ml/kg. Mice were randomly divided into four groups of six animals each. Physical parameters, biochemical parameters related to liver toxicity & nephrotoxicity and hematological parameters were studied as end point of evaluation. We also carried out histopathlogical studies to assess any organ specific toxicity. The present study demonstrated that there were either no or very minimal changes (at high dose) were observed on various physical, biochemical and hematological parameters between Neurotol plus and control group. In conclusion the data of present study suggest that the combination of Mannitol and Glycerol is not associated with any serious adverse effects and is safe therapeutic choice for ICP reduction.

100 Deals associated with Venus Remedies Ltd.

Login to view more data

100 Translational Medicine associated with Venus Remedies Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

15

1

Phase 1 Clinical

Phase 2 Clinical

1

Phase 3 Clinical

Approved

3

9

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ceftriaxone Sodium/Sulbactam Sodium/Edetic Acid ( PBPs x β-lactamase )	Bacterial Infections More	Approved
Cefpirome Sulfate/Sulbactam sodium ( PBPs x β-lactamase )	Sepsis More	Approved
Amikacin/Cefepime ( 30S subunit x PBPs )	Healthcare-Associated Pneumonia More	Approved
CSE-I034	Infectious Diseases More	Phase 3
VRP-I620 ( ETB )	Neoplasms More	Phase 2